Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Cord Blood Transplantation for High-Risk Hematologic Malignancies in Adults
NCT05884333Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival at 1 year. Started May 2023; status: active, not recruiting.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NCT05884333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884333.